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Introduction
The development over the last 10 years of new agents to 
treat chronic hepatitis B and chronic hepatitis C infections 
has led to evaluations of the costs and efficacies of these 
drugs (1).
Although information is available about the prevalence 
of Hepatitis B virus (HBV), risks related to infection and the 
natural history of the disease, less is known about the costs 
related to this disease and to healthcare services. Greater 
knowledge of costs can lead to the correct use of treatment 
agents, determination of priorities and arrangement of future 
healthcare policies (2). Similarly, hepatitis C remains an impor-
tant healthcare problem, especially since the current treat-
ment modalities are not effective in many patients. The rela-
tively low efficacy and high costs of interferon-alpha therapy 
has led to determination of the cost-effectiveness of drugs 
used to treat chronic hepatitis C (3). Few studies, however, 
have assessed indirect costs, including costs caused by loss 
of work. Moreover, no studies to date have analysed the ac-
tual costs, including indirect costs, of hepatitis in our country. 
We have therefore analysed the costs of treatment, follow-up, 
and complications of chronic hepatitis B and hepatitis C infec-
tions to the community.
Materials and Methods
This cross-sectional study involved patients with chronic 
hepatitis B and hepatitis C treated at Pamukkale University 
Hospital Infectious Diseases and Clinical Microbiology Clinic 
between June 30, 2009, and June 30, 2010. The study was 
approved by the local Medical Ethics Committee.
Statistical analysis
Data obtained from participants were analysed using the 
Statistical Package for the Social Sciences (SPSS) for Win-
dows, version 10.5.
Descriptive statistics were reported as mean±standard de-
viation, median, interquartile range, minimum and maximum 
values. As the distribution among the groups was not com-
patible with normal ranges, non-parametric tests were used. 
The Mann-Whitney U Test was used to calculate the associa-
tion between costs and independent variables such as gender. 
The Kruskal-Wallis variance test was used to compare three or 
more independent variables such as marital and educational 
status. Because the age groups were found to be compatible 
with a normal distribution one-way ANOVA was used to evalu-
ate the association between age groups and cost. The Chi-
square test was used to determine the association between 
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primary disease and age groups or gender. A p value <0.05 
was considered statistically significant.
Follow-up and antiviral treatment costs were calculated 
from medical records, with costs determined by analysing 
payments from the Social Security Foundation. To assess indi-
rect costs, questionnaires were submitted to patients, and the 
statements by patients about the loss of productivity, trans-
portation, shelter and nutrition costs during hospital visits 
were used to calculate indirect costs (2). Indirect costs were 
paid by the patients themselves.
Sample election and application
Analysis of medical records identified a total of 525 pa-
tients with chronic hepatitis B and chronic hepatitis C who 
were admitted at least once to our polyclinic. However, during 
the study period, only 284 of these patients were followed-up; 
these 284 patients agreed to participate and were included.
Direct costs included polyclinic costs, total hospital costs, 
follow-up costs and treatment costs, except for the costs of 
antiviral drugs in hospitalised patients, and doctor visits. The 
costs of antiviral treatment consisted only of the costs of the 
drugs themselves. Treatment and follow-up decisions were 
based on current guidelines, including those of the European 
Association for the Study of the Liver (EASL)-2009, the Ameri-
can Association for the Study of Liver Diseases (AASLD)-2009, 
and the Asian Pacific Association for the Study of the Liver 
(APASL)-2008 (4-6).
Indirect costs included patients’ travel costs, loss of work 
during follow-up and treatment, and shelter and nutrition 
charges during the hospital visit. Questionnaire forms were 
submitted to patients face to face and one by one by a single 
examiner.
Patients aged ≥18 years and the parents of the 2 patients 
aged <18 years were informed about the study and provided 
written informed consent.
Results
The 284 patients comprised 232 individuals infected with 
HBV, 50 infected with Hepatitis C virus (HCV), 1 infected with 
HBV and HCV, and 1 infected with 1 HBV and Hepatitis D virus 
(HDV). The 284 patients consisted of 159 (56%) males and 125 
(44%) females, of mean±SD age 43.49±13.07 years (range 16-
75 years). We found that 40 (25.3%) inactive HBV carriers were 
under 30 years old, all patients with cirrhosis were over 40 
years old, and 16 (39%) of the patients with chronic hepatitis 
C were aged 40-49 years.
Occupationally, 73 patients were workers (25.7%), 68 were 
housewives (23.9%), 41 were retired (14.4%), 36 were officer 
workers (12.7%), 24 were farmers (8.5%), 14 were students 
(4.9%), and 7 were unemployed (2.5%).
There were no statistically significantly differences in indi-
rect, hospital, treatment and total costs in patients with chron-
ic hepatitis B and chronic hepatitis C cases by sex and marital 
status (p>0.05). When patients’ educational status was evalu-
ated, we found that hospital and total costs were significantly 
higher for primary school and university graduates than for 
secondary school graduates (p<0.05) and that indirect costs 
were higher for primary school than high school graduates. In 
addition, hospital and total costs were significantly higher for 
university than for high school graduates (p<0.05).
When costs were evaluated according to jobs, we found 
that indirect costs for farmers were significantly higher than for 
housewives, retired persons, students and workers (p<0.05). 
Hospital, treatment, and total costs, however, did not differ 
significantly by occupation (p>0.05).
Prior to the study period, 35 of the 284 (12.3%) patients 
had received antiviral treatment for chronic hepatitis B or 
chronic hepatitis C. Their indirect, hospital, treatment and to-
tal costs did not differ from those of patients who did not 
receive antiviral therapy (p>0.05).
According to guidelines, liver biopsies were taken from 14 
patients. Some patients underwent upper abdominal ultraso-
nography (USG) once or twice per year, 12 patients underwent 
upper abdominal MRI, and 7 underwent dynamic upper ab-
dominal computerised tomography (CT).
Of the 284 patients, 93 (37.2%) received antiviral treat-
ment, including 73 who received therapy for the first time or 
underwent treatment modification during the study period. 
The most frequent antiviral drug was entecavir (n=29; 31.18%) 
followed by tenofovir (n=14; 15.05%).
Of the 50 patients with chronic hepatitis C, 22 received 
antiviral treatment during the study period, including 5 who 
received pegylated interferon-alpha 2a monotherapy because 
of haemodialysis, and 17 who received pegylated interferon-
alpha plus ribavirin. Of the 28 untreated chronic hepatitis C 
patients, 27 had been treated before the study period; of 
these, 25 achieved a sustained viral response and were fol-
lowed-up for relapse and/or hepatocellular carcinoma (HCC), 
and both were refractory to antiviral therapy and were fol-
lowed for complications such as cirrhosis and/or HCC. One 
patient was being prepared for antiviral treatment during the 
study period.
During the study period, 8 patients with possible cirrhosis 
were further investigated. At the beginning of the study period, 
10 patients had cirrhosis. During the study period, one patient 
with relapsed HCV, one with treatment refractory HCV and one 
with chronic hepatitis C were diagnosed with cirrhosis.
Four patients were analysed for antiviral resistance. One 
was resistant to entecavir and switched to tenofovir, one was 
resistant to adefovir and switched to entecavir treatment, and 
one patient treated with tenofovir was switched to entecavir 
because of osteoporosis. 
All patients with cirrhosis, those with chronic hepatitis C 
who were refractory to treatment, those with relapsed chronic 
HBV and chronic HCV, and those co-infected with HBV-HCV 
and HBV-HDV were grouped as patients with complications. 
The indirect, hospital, treatment and total costs of patients 
with chronic hepatitis B were significantly higher than those 
of inactive hepatitis B carriers and patients with chronic hepa-
titis C (p<0.05). The hospital and total costs of patients with 
complications were significantly higher than those of inactive 
HBV carriers and patients with chronic hepatitis C (p<0.05), 
and the indirect and treatment costs of patients with compli-
cations were significantly higher than those of inactive HBV 





Cost of treatment of Hepatitis B and C
The treatment and total costs of patients treated with en-
tecavir were significantly higher than those of patients treat-
ed with tenofovir or lamivudine, or those followed without 
treatment (p<0.05). In addition, the hospital costs of patients 
treated with entecavir were significantly higher than those of 
patients treated with lamivudine (p<0.05). The treatment and 
total costs of patients treated with adefovir were significantly 
higher than those of patients treated with lamivudine, teno-
fovir or entecavir (p<0.05). The hospital, treatment and total 
costs of patients treated with tenofovir were significantly high-
er than those of patients treated with lamivudine (p<0.05).
The treatment and total costs of patients treated with 180 
μg pegylated interferon alpha-2a were significantly higher 
than those of patients treated with lamivudine, entecavir or 
tenofovir (p<0.05), and the indirect, hospital, treatment and 
total costs of patients treated with 180 μg pegylated inter-
feron alpha-2a were significantly higher than those of patients 
who did not receive any antiviral therapy (p<0.05).
The treatment and total costs of patients treated with 135 
μg pegylated interferon alpha-2a were significantly higher 
than those of patients treated with lamivudine (p<0.05). The 
treatment and total costs of patients treated with pegylated 
interferon alpha-2b were significantly higher than those of pa-
tients treated with lamivudine or tenofovir (p<0.05; Table 2).
The indirect, hospital, treatment and total costs of patients 
treated with pegylated interferon-alpha plus ribavirin were 
significantly higher than those of all other patients (p<0.05; 
Table 3). The hospital and total costs of patients with cirrhosis 
were significantly higher than those of patients without cirrho-
sis (p<0.05; Table 4).
Discussion
HBV genotype D is the predominant HBV genotype in Tur-
key; this genotype is resistant to treatment, resulting in relaps-
es, a low response to therapy and high follow-up costs (7-9). It 
is impossible to totally eradicate infections in all patients with 
chronic hepatitis B and chronic hepatitis C. Patients sustain 
material, physical and spiritual losses for many years. Having 
to obtain antiviral drugs from the other countries negatively 
affects the Turkish economy.
Two types of measurements are used to evaluate the 
cost-effectiveness of medical treatment: economic and 
clinical measures (10). Most cost-effectiveness analyses of 
chronic hepatitis utilise Markov models, as complications 
of chronic hepatitis develop over several decades. These 
models are used to evaluate quality of life time adjusted 
costs, including those due to premature death, and these 
models are also used to compare new treatments with cur-
rent treatments (11). Markov models have factors that can 
cause bias, leading to incorrect findings in cost-effective-
ness studies (12).
Cost  Primary disease Patient (n) Mean±SD* Median IR**
Indirect cost*** Chronic Hepatitis B 63 41.10±54.04 28.37 36.94
 Chronic Hepatitis Ca 42 49.14±120.9 10.56 26.39
 Inactive HBVb 158 20.31±38.18 6.60 15.17
 Complicated  21 76.31±141.88 23.09 65.97
Hospital cost*** Chronic Hepatitis Bc 63 241.97±149.64 356.18 388.09
 Chronic Hepatitis C 42 268.08±165.09 253.03 301.82
 Inactive HBV 158 178.10±161.74 152.07 136.46
 Complicatedc  21 313.98±178.75 524.23 675.27
 Chronic Hepatitis Bd 63 4555.06±2671.21 5688.18 3827.24
Treatment cost*** Chronic Hepatitis C 42 3366.61±5576.71 0.00 6743.13
 Complicated 21 4589.77±5574.94 2391.48 7519.83
 Chronic Hepatitis Be 63 4962.94±2650.09 6161.37 3675.73
Total cost*** Chronic Hepatitis C 42 3683.81±5756.68 313.90 7157.34
 Inactive HBV 158 198.40±167.26 173.74 152.77
 Complicatede 21 5142.10±5582.17 3098.23 7875.44
*Standard Deviation
** Interquartile Range
***All costs in United States Dollars
ap<0.05 compared with chronic hepatitis B group
bp<0.05 compared with chronic hepatitis B and complicated groups
cp<0.05 compared with inactive HBV and chronic hepatitis C groups
dp<0.05 compared with chronic hepatitis C group
ep<0.05 compared with inactive HBV and chronic hepatitis C groups
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Cost  Treatment Patient (n) Mean ±SD* Median IR**
Indirect cost*** Entecavir 37 60.98±110.65 26.39 59.70
 Tenofovir 14 32.68±16.01 32.99 32.99
 Lamivudine 13 65.58±97.31 39.58 40.57
 Adefovir 6 23.97±21.66 18.14 30.51
 Pegifn2a180a 9 143.53±193.91 59.40 221.67
 Pegifn2a135 5 36.30±32.74 31.67 63.66
 Pegifn2b 9 70.08±153.00 19.80 45.85
 NT 191 19.11±35.30 6.60 15.17
Hospital cost*** Entecavir  37 405.92±207.20 387.25 250.38
 Tenofovir  14 484.30±317.81 383.80 266.66
 Lamivudineb 13 261.28±166.57 222.26 226.38
 Adefovir 6 250.19±226.75 224.40 453.44
 Pegifn2a180 9 421.82±163.74 457.71 248.42
 Pegifn2a135 5 360.42±147.64 348.93 273.62
 Pegifn2b 9 414.90±200.95 420.57 326.09
 NTc 191 190.95±172.65 156.62 142.37
Treatment cost*** Entecavir 37 5253.82±1772.93 6186.83 1455.84
 Tenofovird 14 4460.40±1514.21 5241.83 1453.01
 Lamivudinee 13 379.6±174.48 498.75 231.36
 Adefovirf 6 8008.76±203.62 7925.64 124.69
 Pegifn2a180 9 9359.26±4353.52 9041.98 5949.85
 Pegifn2a135 5 5955.18±1751.71 6702.31 3204.08
 Pegifn2b 9 11213.08±7692.44 8487.86 15684.39
Total cost*** Entecavirg 37 5720.72±1711.78 6411.08 1340.26
 Tenofovirh 14 4977.37±1404.40 5570.02 1360.29
 Lamivudinei 13 706.46±158.46 694.88 128.97
 Adefovir 6 8282.92±202.98 8339.97 531.45
 Pegifn2a180 9 9924.61±4552.37 9526.52 5974.26
 Pegifn2a135 5 6351.88±1781.30 7287.35 3233.37
 Pegifn2b 9 11698.05±7783.46 9001.91 15544.11
 NT 191 210.05±176.35 180.50 159.85
*Standard Deviation
**Interquartile Range
***All costs calculated in United States Dollars
NT: non treated
ap<0.05 compared with NT
bp<0.05 compared with entecavir and tenofovir
cp<0.05 compared with 135 and 180 μg pegylated interferon alpha-2a and -2b
dp<0.05 compared with adefovir, entecavir and 180 μg pegylated interferon alpha-2a and -2b
ep<0.05 compared with adefovir, tenofovir, entecavir and 135 and 180 μg pegylated interferon alpha-2a and -2b
fp<0.05 compared with adefovir
gp<0.05 compared with adefovir and 180 μg pegylated interferon alpha-2a
hp<0.05 compared with adefovir, entecavir, lamivudine and 180 μg pegylated interferon alpha- 2a and -2b
ip<0.05 compared with entecavir, adefovir and 135 and 180 μg pegylated interferon alpha 2a and -2b





Cost of treatment of Hepatitis B and C
We did not evaluate cost-effectiveness because this would 
require decades of follow-up. When we searched PubMed us-
ing the key words “cost, hepatitis B” and “cost, hepatitis C” 
we could not find any studies of real patients that included 
decades of follow up. Among the advantages of our study 
was that we included all patients with chronic hepatitis B 
and C followed up by our clinic and hospitalised during the 
study period and that we evaluated treatment, hospital and 
indirect costs for real patients. We therefore evaluated actual 
treatment costs by using real drug doses. In contrast, studies 
based on models did not evaluate indirect costs.
One study (2) found that most of the total costs consisted 
of indirect costs, with most of the latter consisting of loss of 
work. Loss of efficiency was highest in patients with acute and 
chronic hepatitis B and the premature death rates were higher 
in patients with cirrhosis and/or HCC.
In our study, most of the total costs consisted of treatment 
costs. The drugs had to be obtained from abroad at high costs. 
Workers generally came to the hospital between shifts to prevent 
the loss of work, and most of these patients used free transporta-
tion, thus minimising indirect costs as a fraction of total costs.
We found that indirect costs to primary school graduates 
were the highest. Most of these individuals were farmers who 
had to come from rural areas. Thus, their higher indirect costs 
were due to the costs of transportation.
We found that total costs were 10-fold higher in patients 
with than without cirrhosis, with most of these costs being 
due to hospital costs. A previous study showed that the direct 
costs of patients with cirrhosis were 3-fold higher than those 
of patients with chronic hepatitis B, as were indirect costs (2). 
Although hospital costs were 10-fold higher in patients with 
compensated cirrhosis than those with chronic hepatitis B, 
their antiviral treatment costs were similar (13). We found that 
the frequencies of invasive examinations and hospitalisation 
were higher in patients with than without cirrhosis, but that 
the treatment costs of these two groups did not differ signifi-
cantly because all of our patients with cirrhosis had compen-
sated cirrhosis, with similar treatments for these two groups.
A cost comparison in inactive HBV carriers without any 
treatment, HBV patients who took lamivudine monotherapy 
for one year and HBV patients who took lamivudine-adefovir 
therapy for five years found that, when the costs of the treat-
ments were evaluated together with their ability to stop dis-
ease progression, the lamivudine-adefovir combination was 
optimal (14). In Turkey, the Social Security Foundation does 
not pay the costs of combination therapy for chronic hepatitis 
Cost  Cirrhosis Patients (n) Mean±SD* Median IR ** P
Indirect cost*** No  271 30.08± 62.41 11.22 25.73 0.316
 Cirrhosis 13 100.79±177.48 20.45 169.88
Hospital cost*** No  271 243.77±200.28 211.51 227.00 0.001
 Cirrhosis 13 495.27±291.83 524.23 376.35
Treatment cost*** No  271 1816.40±3593.07 0.000 2359.60 0.058
 Cirrhosis  13 2500.50±2937.17 2300.13 4715.29
Total cost*** No  271 2090.26±3693.50 267.87 2780.23 0.008
 Cirrhosis  13 3096.55±3067.14 2976.29 4667.79
*Standard Deviation
**Interquartile Range
***All costs calculated in United States Dollars
Table 4. Evaluation of the costs in patients with and without cirrhosis
Costs  Additional therapy Patients (n) Mean±SD* Median IR ** P
Indirect cost*** No  267 28.87±57.91 10.56 26.39 0.037
 Yes 17 103.19±178.76 20.45 62.67
Hospital cost*** No 267 246.17±209.36 211.51 226.94 0.002
 Yes 17 398.54±194.68 429.94 343.85
Treatment cost*** No 267 1307.38±2492.45 0.000 498.75 0.0001
 Yes 17 10334.15±6326.05 8487.86 8700.68
Total cost*** No 267 1582.42±2582.57 259.86 641.18 <0.0001
 Yes  17 10835.88±6452.30 9001.91 9087.55
*Standard Deviation
**Interquartile Range
***All costs calculated in United States Dollars
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B so none of our chronic hepatitis B patients took combina-
tion therapy. Moreover, the previous study did not include the 
costs of the new generation of antiviral agents, such as teno-
fovir and entecavir.
Comparisons of lamivudine and pegylated interferon-al-
pha 2a therapy for 1 year in patients with chronic hepatitis B 
showed that peg-interferon alpha-2a was more cost-effective, 
but all of those patients were naive to treatment and at the 
same disease stage (15, 16). We found that the costs of pe-
gylated interferon alpha-2a and -2b were higher than those of 
lamivudine, but hospital costs did not differ significantly. Our 
study was more encompassing, in that it included patients not 
naive to treatment and at different disease stages.
A comparison of lamivudine with peg-interferon followed 
by lamivudine showed that the mean costs of the former were 
14,100 United States Dollars (USD) higher. In contrast, we 
found that previous antiviral treatment did not significantly af-
fect overall costs.
A comparison of tenofovir, entecavir, telbivudine and ade-
fovir in patients with chronic hepatitis B showed that tenofovir 
was more cost-effective than the other agents (17). Similarly, 
we found that the treatment and total costs of tenofovir were 
less than those of entecavir and adefovir.
As no previous studies have assessed the costs of chronic 
hepatitis C based on real patients, we compared our findings 
with those of studies using Markov models.
Asymptomatic chronic hepatitis C was found to significant-
ly reduce productivity and ability to work and was associated 
with high healthcare costs (18). Mean annual income was 8352 
USD lower in individuals with than without HCV. We found 
that the indirect, hospital, treatment and total costs of chronic 
hepatitis C patients were less than those of chronic hepatitis B 
patients, but higher than those of inactive HBV carriers. While 
50% of our chronic HCV patients achieved viral response, they 
were seen at our hospital at 6-12 month intervals for the evalu-
ation of HCC and/or relapse, reducing their ability to work and 
increasing treatment costs.
The combination of pegylated interferon-alpha and ribavi-
rin was found to be more cost-effective than pegylated inter-
feron-alpha alone in patients with chronic hepatitis C (19). This 
model assumed that a sustained viral response would occur 
and that survival would be the same as in individuals without 
chronic hepatitis C. In practice, however, some patients with 
sustained viral response relapse, whereas some refractory to 
treatment progress to cirrhosis.
A model of chronic hepatitis C patients at age 40 years 
with high ALT levels found that the cost-benefits of treatment 
would be greater in women than in men, primarily because the 
probability of progressing to cirrhosis is lower in women (20). 
That model, however, did not evaluate relapsed patients and 
those refractory to treatment. We found that 75% of HCV pa-
tients with cirrhosis were males, whereas 66.7% of those who 
relapsed were females. Comorbid factors should therefore be 
considered when evaluating the effectiveness of treatment.
This study had several limitations. First, it was hospital-
based; therefore, the results cannot be generalised to all 
patients with viral hepatitis. In addition, none of our pa-
tients had undergone liver transplantation or had liver 
cancer, preventing the evaluation of costs at all stages of 
chronic hepatitis B and C.
In conclusion, chronic hepatitis B and C remain impor-
tant healthcare problems, with costs increasing with stage 
of liver disease. Treatment costs constituted the largest 
fraction of total costs. The treatment and total costs of ad-
efovir therapy were higher than those of lamivudine, teno-
fovir or entecavir therapy. The direct and indirect costs of 
these diseases on the Turkish economy suggest the need 
for greater prevention.
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